Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
Stocks · News reference
Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced successful
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Lyell Immunopharma, Inc. (LYEL)
Filed: 2026-09-10 AccNo: 0001193125-26-387890 Size: 161 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Lyell Immunopharma shares are trading higher after Stifel initiated coverage on the stock with a Buy rating and announced a $36 price target.